Level Four Advisory Services LLC Buys 3,845 Shares of Johnson & Johnson $JNJ

Key Points

• Level Four Advisory Services LLC increased its stake in Johnson & Johnson by 6.1%, acquiring an additional 3,845 shares, bringing its total ownership to 66,662 shares valued at $11,055,000.
• Johnson & Johnson recently reported quarterly earnings of $2.77 EPS, surpassing analyst estimates, with revenues of $23.74 billion—a 5.8% year-over-year increase.
• The company announced a quarterly dividend of $1.30 per share, yielding 2.9%, with shareholders of record set to receive it on September 9th.

Level Four Advisory Services LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 66,662 shares of the company's stock after acquiring an additional 3,845 shares during the period. Level Four Advisory Services LLC's holdings in Johnson & Johnson were worth $11,055,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the first quarter worth approximately $47,000. von Borstel & Associates Inc. bought a new position in Johnson & Johnson during the first quarter valued at approximately $49,000. Capital A Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $50,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $52,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Guggenheim reissued a "neutral" rating and issued a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Bank of America raised their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Barclays increased their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Price Performance

JNJ opened at $177.7060 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a market capitalization of $427.98 billion, a PE ratio of 19.01, a price-to-earnings-growth ratio of 2.24 and a beta of 0.41. The stock's 50 day moving average price is $162.13 and its 200-day moving average price is $158.73. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $178.18.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.